REPL vs IOVA vs ADCT vs IMVT

For growth investors, Iovance Biotherapeutics, Inc.

(IOVA) is the stronger pick with 60. 6% revenue growth year-over-year, versus 14. 9% for ADC Therapeutics S. A. (ADCT). Analysts rate Replimune Group, Inc. (REPL) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +62. 4%, compared to -90. 7% for Replimune Group, Inc. (REPL). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus ADCT's -87. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Replimune Group, Inc.

(REPL) is the lower-risk stock at 0. 83β versus Iovance Biotherapeutics, Inc. 's 2. 01β — meaning IOVA is approximately 141% more volatile than REPL relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 18% for Replimune Group, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Iovance Biotherapeutics, Inc.

(IOVA) is pulling ahead at 60. 6% versus 14. 9% for ADC Therapeutics S. A. (ADCT). On earnings-per-share growth, the picture is similar: ADC Therapeutics S. A. grew EPS 30. 9% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Replimune Group, Inc.

(REPL) is the more profitable company, earning 0. 0% net margin versus -175. 3% for ADC Therapeutics S. A. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REPL leads at 0. 0% versus -153. 1% for IOVA. At the gross margin level — before operating expenses — IOVA leads at 97. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Replimune Group, Inc.

(REPL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 83)). Iovance Biotherapeutics, Inc. (IOVA) carries a higher beta of 2. 01 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (REPL: -78. 0%, IOVA: -34. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: REPL is a small-cap quality compounder stock; IOVA is a small-cap high-growth stock; ADCT is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.